Login to Your Account



IN THE CLINIC

Mezzion’s PDE5 inhibitor enters U.S. trials for Fontan patients

By Shannon Ellis
Staff Writer

Wednesday, January 22, 2014

SHANGHAI – Mezzion Pharma Co. Ltd., of Seoul, South Korea, has signed an agreement with New England Research Institutes Inc. (NERI) to conduct government-sponsored clinical trials for udenafil. A long-acting phosphodiesterase type 5 (PDE5) inhibitor first approved in Korea and Russia for erectile dysfunction, udenafil will be trialed as a treatment for adolescents who face shortened lifespans due to reduced heart function due to congenital heart defects.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription